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Objective: To compare the accuracy of standard supple-
mentary views and GE digital breast tomosynthesis (DBT)
for assessment of soft-tissue mammographic abnormalities.
Methods:Women recalled for further assessment of soft-
tissue abnormalities were recruited and received stan-
dard supplementary views (typically spot compression
views) and two-view GE DBT. The added value of DBT in
the assessment process was determined by analysing
data collected prospectively by radiologists working up
the cases. Following anonymization of cases, there was
also a retrospective multireader review. The readers first
read bilateral standard two-view digital mammography
(DM) together with the supplementary mammographic
views and gave a combined score for suspicion of
malignancy on a five-point scale. The same readers then
read bilateral standard two-view DM together with two-
view DBT. Pathology data were obtained. Differences
were assessed using receiver operating characteristic
analysis.
Results: The study population was 342 lesions in
322 patients. The final diagnosis was malignant in 113
cases (33%) and benign/normal in 229 cases (67%). In the
prospective analysis, the performance of two-view DM
plus DBT was at least equivalent to the performance of
two-view DM and standard mammographic supplemen-
tary views—the area under the curve (AUC) was 0.946
and 0.922, respectively, which did not reach statistical
significance. Similar results were obtained for the retro-
spective review—AUC was 0.900 (DBT) and 0.873
(supplementary views), which did not reach statistical
significance.
Conclusion: The accuracy of GE DBT in the assessment
of screen detected soft-tissue abnormalities is equiva-
lent to the use of standard supplementary mammo-
graphic views.
Advances in knowledge: The vast majority of evidence
relating to the use of DBT has been gathered from
research using Hologic equipment. This study provides
evidence for the use of the commercially available GE
DBT system demonstrating that it is at least equivalent to
supplementary mammographic views in the assessment
of soft-tissue screen-detected abnormalities.
INTRODUCTION
Supplementary mammographic views have traditionally
been a crucial part of the assessment process in women
recalled following an abnormal screening mammogram.
These might include spot compression views (SCVs),
lateral projections and extended or exaggerated cranio-
caudal (CC) views. Their purpose is to confirm the pres-
ence and characterize a true breast lesion rather than a
pseudoabnormality simulated by summation of normal
breast tissue.
Digital breast tomosynthesis (DBT) is an advanced
form of digital mammography (DM), providing three-
dimensional-like reconstructed images of the breast tissue.
This has the potential to reduce the tissue overlap effect
thereby improving the sensitivity and specificity of
a screening programme, by improving margin character-
ization and eliminating summation effects.1 The improved
specificity offered by DBT can also be utilized in the as-
sessment of screen-detected abnormalities. Several studies
have already suggested that DBT can replace the traditional
supplementary mammographic views in the assessment of soft-
tissue breast lesions, with performance at least equivalent.2–7
DBT is currently available from multiple vendors. Each system
differs in design, with significant variations in parameters such
as tube motion, angle range, number of projections and pro-
cessing algorithms. Each of these features has the potential to
affect clinical performance.8 The majority of published DBT
research has been conducted on Hologic equipment (Bedford,
MA). Concern has been raised that evidence produced from
studies using one system cannot necessarily be extrapolated to
other manufacturers’ devices and that further research using
other vendors’ devices has been suggested before other manu-
facturer DBT systems are introduced into routine clinical prac-
tice replacing established assessment protocols.
The aim of this study was to assess whether the performance of
GE Healthcare (Buc, France) DBT (GE DBT) is equivalent to
standard supplementary mammographic views and can poten-
tially replace their use in the assessment of screen-detected soft-
tissue abnormalities.
METHODS AND MATERIALS
This was a dual-centre paired comparison study involving
a prospective component assessing the clinical utility of GE DBT
as an adjunct tool in screening assessment and a retrospective
multireader component comparing diagnostic performance of
GE DBT vs standard supplementary views in the assessment
of soft-tissue screen-detected abnormalities. The study was
approved by the local National Health Service (NHS) Research
Ethics Committee, received support from the National Cancer
Research Network and was funded by GE Healthcare. GE
Healthcare had no control over study design, data collection,
analysis or presentation of the results.
The study group comprised women requiring further mam-
mographic work-up of screen-detected soft-tissue lesions at two
NHS breast screening sites between 1 February and 30 Sep-
tember 2014. Prior to participation, written consent was
obtained from all women. The standard supplementary views
obtained were usually SCVs in standard mediolateral oblique
(MLO) and CC planes. Occasionally, extended CC views, lateral
projections or magnification views were obtained if felt clinically
indicated. DBT views were obtained in MLO and CC projections
of the breast being assessed. DBT was performed on a commer-
cially available GE DBT system (SenoClaire®). The GE system
uses a “step and shoot” acquisition with nine exposures over
a 25° gantry angle and uses iterative reconstruction techniques.
Supplementary views were performed on either a GE Essential
or GE DS full-field DM machine. Images were reviewed and
interpreted on a GE Image Diagnostic International workstation.
For the prospective part of the study, standard supplementary
views and DBT images were reviewed by two consultant radi-
ologists conducting the clinic. It is our standard practice for two
radiologists to review supplementary imaging performed in the
work-up of screen-detected abnormalities to reduce the likeli-
hood of false-negative assessment. A consensus imaging score
Figure 1. Recruitment and assessment process. ALH, atypical lobular hyperplasia; DBT, digital breast tomosynthesis; DCIS, ductal
carcinoma in situ.
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was prospectively assigned for both modalities prior to ultra-
sound being performed. Typically, the standard supplementary
views were reviewed and scored first followed by the DBT
images. The imaging score used was the UK Royal College of
Radiologists 1–5 score.9 Decisions on the need for biopsy were
made on a case-by-case basis, but if the supplementary mam-
mographic views were deemed abnormal and DBT normal, then
biopsy was still attempted as the supplementary mammographic
views remained the standard of care. However, if supplementary
mammographic views were deemed normal but DBT showed
a persistent or additional abnormality, then management was
changed accordingly. Data were also prospectively recorded on
size and multifocality for both modalities. The radiologists
working up the cases were also asked to rate the usefulness of the
DBT images in their decision-making.
All images were then anonymized and retrospectively reviewed
by one of eight specialist breast radiologists not involved in the
initial assessment. The radiologists’ breast imaging experience
ranged from 7 to 24 years (median 15 years). All radiologists
fulfilled the NHS Breast Screening Programme (NHSBSP)
Quality Assurance Criteria for screening mammography film
reading and assessment and have undergone specialist training
in interpretation of DBT images.10 As a minimum, this involved
a 1-day training course involving review of 80 cases with both
two-dimensional (2D) full-field DM and DBT. The first review
involved analysis of the two-view digital screening mammogram
with the supplementary assessment views (usually SCV). The
second review took place at least 3 weeks later and involved
analysis of the two-view DM with DBT. The radiologist
undertaking the retrospective review was blinded to the assess-
ment outcome. For both of the retrospective reviews, an imaging
score was assigned using the UK Royal College of Radiologists
1–5 score9. Histopathology provided the ground truth outcome
for those subject to biopsy.
For both components of the study, performance of the supple-
mentary mammographic views and DBT was determined by re-
ceiver operating characteristic (ROC) curves. Areas under the
curve (AUCs) were compared using the method of DeLong et al.11
A x2 test was used to determine significance in sensitivity, spec-
ificity and positive-predictive value (PPV) between the two mo-
dalities. A p-value of,0.05 was regarded as statistically significant.
RESULTS
324 women were recruited to take part in the study. 344 lesions
were assessed in 324 patients. Two patients were later excluded
because they were diagnosed with non-breast malignancies
(one aggressive fibromatosis and one primary lymphoma). The
study population therefore consisted of 342 lesions in
322 patients. The predominant mammographic abnormalities
undergoing assessment were masses (50%), distortions
(13.5%) and asymmetric densities (36.5%). Microcalcification
was an associated feature in 3.8%, but patients had not been
invited to participate when microcalcification was the pre-
dominant mammographic feature. Additional mammographic
views were performed in all cases. Occasionally, SCVs needed
to be repeated because of the lesion being missed. Repeat SCVs
were requested by the assessing radiologists in 49 of the
322 patients (15.2%). There were no instances where DBT was
Table 1. Final pathology and imaging scores prospectively assigned to each soft tissue abnormality during the assessment work-up
following screening recall
Final pathology after full assessment Images read
Imaging score (n5 342)
M1/2 M3 M4 M5
Normal/Benign
2D plus SCV 180 42 6 1
2D plus DBT 189 29 9 2
Malignant
2D plus SCV 11 17 35 50
2D plus DBT 7 16 25 65
2D, standard two-dimensional digital mammography; DBT, digital breast tomosynthesis; SCV, spot compression views and other supplementary
mammographic views.
Table 2. Accuracy of digital breast tomosynthesis (DBT) and supplementary mammographic views in the assessment of soft-tissue
abnormalities from the imaging scores prospectively assigned to each lesion during the assessment work-up following
screening recall
Measured statistic 2D and SCV (%) 2D and DBT (%) x2 significance (two-sided)
Absolute sensitivity (M5) 44.24 57.52 0.045
Complete sensitivity (M3,4,5) 90.26 93.80 0.326
Specificity 78.60 82.53 0.288
M5 PPV 98.03 97.01 0.726
M1/2 NPV 94.24 96.42 0.307
2D, standard two-dimensional digital mammography; NPV, negative-predictive value; PPV, positive-predictive value; SCV, spot compression views and
other supplementary mammographic views.
Full paper: GE tomosynthesis vs supplementary mammographic views BJR
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repeated. Consequently, the mean number of additional views
was 2.3 (range 1–5). For DBT, the average mean glandular dose
for an MLO of a 50–60mm breast was 1.50mGy for the two
centres.12,13 All lesions underwent an ultrasound scan, with any
biopsies performed under ultrasound or stereotactic guidance
as appropriate.
Figure 1 shows a flow diagram of the trial. The final diagnosis
was malignant in 113 lesions (33%) and benign or normal in
229 lesions (67%). Of the malignant lesions, 107 (94.7%) were
invasive cancers and 6 (5.3%) were ductal carcinoma in situ.
Of the 229 lesions with a final outcome of benign or normal,
54 patients (23.5%) had a biopsy at assessment. 44 of these
had a benign biopsy result and were discharged back to nor-
mal screening. The other 10 patients required a diagnostic
excision of the lesion—7 of these patients had a final pathological
diagnosis of radial scar. There has been 1 interval cancer in the
group of 229 patients with a normal/benign assessment outcome
which was diagnosed 12 months after the assessment process.
Prospective analysis
There were three patients where DBT demonstrated multifocal
disease thought to be unifocal on the screening mammogram
and supplementary mammographic views. These additional
lesions are included in the total of 342 lesions assessed in the
322 patients. There were no cases where the supplementary
mammographic views demonstrated multifocal disease thought
to be unifocal on DBT.
The imaging scores assigned to each lesion prospectively following
supplementary views and DBT during the assessment work-up
are shown in Table 1, with sensitivities, specificity, PPV and
negative-predictive value (NPV) for each technique shown in
Table 2. DBT demonstrated significantly higher absolute sensi-
tivity than standard supplementary mammographic views
(p5 0.045). There was no significant difference between the
overall performance of standard supplementary views and DBT as
determined by ROC analysis with the AUC being 0.922 [95%
confidence interval (CI) 0.889–0.948] and 0.946 (95% CI
0.917–0.968), respectively (Figure 2).
The radiologists working up the cases found DBT to be useful in
56.9% of cases, the main reason quoted was improved margin
delineation (54.7%) with the second most common reason be-
ing that it helped confirm the benign nature of lesions (35.3%).
Retrospective analysis
During the retrospective review, an additional nine lesions were
documented by the readers, but all were categorized as benign. The
retrospective review generated no additional malignant lesions. A
total of 351 lesions were documented in the 322 patients, of which
the final diagnosis was malignant in 113 (32.2%) lesions and be-
nign or normal in 238 (67.8%) lesions. The imaging scores assigned
to each lesion during the retrospective reader review of the sup-
plementary views and DBT are shown in Table 3 with sensitivities,
specificity, and NPV and PPV shown in Table 4. There was no
significant difference between the overall performance of the
standard supplementary views and DBT as determined by ROC
analysis with the AUC being 0.873 (95% CI 0.834–0.906) and 0.900
(95% CI 0.864–0.929), respectively (Figure 3).
Figure 2. Overall prospective performance of standard two-
dimensional (2D) digital mammography and digital breast
tomosynthesis (DBT) vs 2D and spot compression views (SCV)
in the assessment work up of screen detected soft tissue
abnormalities. AUC, area under the curve; ROC, receiver
operating characteristic.
Table 3. Final pathology and imaging scores assigned to each soft-tissue abnormality during the retrospective reader review
Final pathology after full assessment Images read
Imaging score (n5 351)
M1/2 M3 M4 M5
Normal/Benign
2D plus SCV 168 60 8 2
2D plus DBT 172 54 8 4
Malignant
2D plus SCV 9 23 41 40
2D plus DBT 7 22 30 54
2D, standard two-dimensional digital mammography; DBT, digital breast tomosynthesis; SCV, spot compression views and other supplementary
mammographic views.
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DISCUSSION
X-ray mammography is our current primary diagnostic tool for
detection of breast cancer, however, it has limitations in terms of
both sensitivity and specificity. Its poor specificity means that
approximately 75% of women recalled following screening
mammography in the UK will not have cancer but will be
subjected to further tests including biopsy. Further imaging
investigation has traditionally involved supplementary mam-
mographic views to investigate potential masses, asymmetries
and distortions, most often SCVs performed in MLO and CC
projections. The results of this study show that GE DBT is at
least equivalent to the use of these supplementary mammo-
graphic views in the assessment of screen-detected soft-tissue
abnormalities with improved absolute sensitivity in the pro-
spective evaluation.
Others have also demonstrated equivalent or improved accuracy
of DBT compared with supplementary mammographic views in
the assessment process.2–7 It has recently been shown that when
DBT is introduced as the primary screening test, significantly
fewer recalled women required supplementary mammographic
views as part of the assessment work-up.14 There have also been
two recently published overviews of current evidence on
DBT.1,15 Houssami and Skaane1 concluded that the addition of
DBT to standard mammography for mammographic in-
terpretation or for assessment or triage of screen-recalled ab-
normalities increases accuracy. Alakhras et al15 concluded that
DBT has shown promise in comparison with additional 2D
views, demonstrating the same or higher diagnostic accuracy
than digital SCVs. This body of evidence has led to changes in
protocols with a switch from SCVs to DBT in the further
evaluation of mammographic abnormalities found at screening
and in symptomatic diagnostic practice.
The vast majority of the research to date on DBT has been
performed on Hologic DBT equipment and very little literature
exists on other commercially available systems. Concern has
been raised that evidence acquired from one vendor’s device can
not necessarily be extrapolated to other manufacturers, and
more information is needed on the effectiveness of non-Hologic
DBT systems.16 In the UK breast-screening programme, the
recommendation that DBT can be used to replace SCVs only
extends to Hologic equipment.17
The current commercially available DBT systems differ in design
with significant variations in parameters such as tube motion,
angle range, number of projections and processing algorithms.
Each of these features has the potential to affect clinical per-
formance.8 Hologic DBT uses a pulsed acquisition during
a continuous sweep of the detector with 15 exposures over
a 15° angle range and uses a filtered back projection algorithm
for image processing. The GE system uses a “step and shoot”
acquisition with 9 exposures over a 25° gantry angle and uses
iterative reconstruction techniques. The advantages of these
different approaches are open to debate but can affect image
quality. A wider tube angle provides better depth resolution,
whereas a narrow one improves in-plane resolution. Iterative
reconstruction is said to improve visualization of masses and
soft-tissue margins, whereas filtered back projection can en-
hance the conspicuity of microcalcifications.18 Sechopoulos19,20
Table 4. Accuracy of digital breast tomosynthesis (DBT) and supplementary mammographic views in the assessment of soft-tissue
abnormalities from the imaging scores assigned during the retrospective reader review
Measured statistic 2D and SCV (%) 2D and DBT (%) x2 significance (two-sided)
Absolute sensitivity (M5) 35.39 47.78 0.059
Complete sensitivity (M3,4,5) 92.03 93.80 0.604
Specificity 70.58 72.26 0.685
M5 PPV 95.23 93.10 0.657
M1/2 NPV 94.90 96.08 0.708
2D, standard two-dimensional digital mammography; NPV, negative-predictive value; PPV, positive-predictive value; SCV, spot compression views and
other supplementary mammographic views.
Figure 3. Overall performance of standard two-dimensional
(2D) digital mammography and digital breast tomosynthesis
(DBT) vs 2D and spot compression views (SCVs) in the
assessment of screen-detected soft-tissue abnormalities dur-
ing the retrospective reader review. AUC, area under the curve;
ROC, receiver operating characteristic.
Full paper: GE tomosynthesis vs supplementary mammographic views BJR
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has produced detailed publications on the technical aspects of
DBT and some of the main differences between different man-
ufacturers’ equipment, but detailed discussion is beyond the
scope of this article. This study contributes to the evidence that
the performance of the commercially available GE system per-
formance is comparable to that seen with Hologic equipment in
the evaluation of screen-detected soft-tissue abnormalities.
We did not use DBT to assess any patients with micro-
calcification because previous studies have found that the im-
proved accuracy for DBT in the work-up of screen-detected
abnormalities only applied to soft-tissue abnormalities. The
detection and characterization of microcalcifications with DBT
is a more controversial area. Kopans et al21 reported equal or
better visualization of calcifications with DBT, whereas others
have reported improved sensitivity of standard 2D DM com-
pared with DBT.22 Morel et al7 found no difference in the per-
formance of DBT compared with magnification mammography
in the work-up of screen-detected microcalcifications. In ret-
rospect, it may have been useful to include some calcified lesions
in this study, as there may be a manufacturer-specific difference.
The dose of GE DBT is only marginally more than standard 2D
DM. For DBT, the average mean glandular dose for an MLO of
a 50–60mm breast was 1.50mGy for the two centres.12, 13 The
corresponding doses for standard 2D mammography on these
systems are 1.43mGy (Derby) and 1.14mGy (Nottingham), which
fall well below the national diagnostic reference level for mam-
mography of 3.5mGy mean glandular dose to a lateral oblique
view of a 55-mm compressed breast. Performing SCVs can be
technically challenging for the radiographer, and repeats are not an
uncommon occurrence, whereas DBT uses standard patient po-
sitioning and so is technically easier to perform. During the study,
repeat SCVs were requested in 15.2% of assessment work-ups
because of the lesion having been missed, adding to the radiation
dose, and potentially increasing assessment time and patient
anxiety. The advantage of DBT is that it provides additional in-
formation of the whole of the imaged breast, avoiding repeat
exposures. When the repeat views are taken into account, there is
a potential dose saving by replacing supplementary mammo-
graphic views with DBT. The ability to image the whole of the
breast with DBT also has the advantage of identifying unsuspected
multifocal disease as occurred in three patients in this study.
The utility of DBT is not just down to its accuracy. The radi-
ologists working up the cases found the additional information
provided by DBT in lesion work-up helpful in the decision-
making process over and above that obtained from the
supplementary mammographic views. The assessing radiologists
found DBT to be useful in 56.9% of assessment cases with the
main reason quoted being improved margin delineation (54.7%)
and the second most common reason being that it helped
confirm the benign nature of lesions (35.3%). Other potential
advantages of DBT over supplementary mammographic views
are improved lesion localization in three dimensions, aiding
ultrasound and biopsy targeting.
There are some potential problems with the study. The pro-
spective review can be criticized for bias as the assessing radiol-
ogists were not blinded to the results of DBT and supplementary
mammographic views during lesion work-up. By contrast, the
readers in the retrospective review had no knowledge of the as-
sessment outcome, and reading of DBT and supplementary
mammographic views was separated by at least 3 weeks. Another
problem of the study is the relatively short follow-up time for
the benign and normal cases, but because of the paired nature
of the study, meaningful conclusions can still be drawn. The
study was designed to compare the performance of GE DBT
to supplementary mammographic views in the assessment of
screen-detected soft-tissue abnormalities, and we have shown
equivalence in the characterization and diagnosis of soft-tissue
abnormalities. Further research is still needed, with GE DBT to
confirm the improved sensitivity and specificity shown with
Hologic DBT in the detection of malignancy.
In conclusion, GE DBT is at least equivalent to supplementary
mammographic views in the assessment of soft-tissue screen-
detected abnormalities. The vast majority of evidence relating to
the use of DBT has been gathered from research using Hologic
equipment. A major strength of this study is that it provides
evidence for the use of the commercially available GE DBT
system. The findings can be used to support a change in the
assessment protocols allowing the replacement of supplementary
mammographic views with GE DBT for the assessment of screen
detected soft-tissue abnormalities.
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